Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • Concanamycin A: Selective V-ATPase Inhibitor for Cancer B...

    2026-01-22

    Concanamycin A: Selective V-ATPase Inhibitor for Cancer Biology Research

    Executive Summary: Concanamycin A is a highly potent and selective inhibitor of vacuolar-type H+-ATPase (V-ATPase), with an IC50 of ~10 nM in mammalian cells. It directly targets the Vo subunit c, irreversibly blocking proton transport across endosomal and lysosomal membranes, and thereby disrupts endosomal acidification and intracellular trafficking [APExBIO]. This disruption leads to apoptosis induction in multiple tumor cell lines and significantly attenuates cell invasiveness. Concanamycin A is widely adopted as a biochemical tool in the investigation of V-ATPase-mediated signaling pathways and mechanisms of therapeutic resistance. Its solubility profile, storage parameters, and experimental use conditions are well established for reproducible results in cancer biology research [BCA-Protein].

    Biological Rationale

    V-ATPases are multisubunit proton pumps essential for organelle acidification, protein sorting, and signal transduction in eukaryotic cells. Dysregulation of V-ATPase function is implicated in cancer progression, metastasis, and resistance to apoptosis. Targeted inhibition of V-ATPase activity disrupts the pH gradient required for endosomal trafficking, lysosomal degradation, and autophagic flux. Concanamycin A, as a selective V-type H+-ATPase inhibitor for cancer research, provides a precise method to interrogate the role of organelle acidification in cellular signaling and tumor cell viability (Zhang et al., 2025). Unlike non-selective or weak inhibitors, Concanamycin A offers high potency and selectivity, enabling robust mechanistic studies.

    Mechanism of Action of Concanamycin A

    Concanamycin A binds directly to the Vo subunit c of the V-ATPase complex. This interaction blocks proton translocation across the membrane, elevating endosomal and lysosomal pH. As a result, acid-dependent processes such as receptor internalization, protein degradation, and extracellular matrix pH maintenance are disrupted. Inhibition of endosomal acidification impedes intracellular trafficking, leading to accumulation of undegraded proteins and triggering apoptosis pathways in susceptible cancer cell lines. Concanamycin A also modulates apoptosis-related processes, such as attenuation of TRAIL-induced caspase activation. These mechanistic insights form the foundation for its application in studies of V-ATPase-mediated signaling pathways, therapeutic resistance mechanisms, and tumor cell invasion [Vatalis]. For a direct comparison to related inhibitors and more on workflow optimization, see this guide, which contrasts broader protocol issues with the mechanistic depth provided here.

    Evidence & Benchmarks

    • Concanamycin A displays an IC50 of ~10 nM for V-ATPase inhibition in mammalian cells, as measured by disruption of proton transport and organelle acidification (APExBIO product documentation).
    • Direct binding to the Vo subunit c has been demonstrated via structural and biochemical assays (Zhang et al., 2025).
    • At 20 nM for 60 minutes, Concanamycin A induces apoptosis in oral squamous cell carcinoma, prostate cancer, HCT-116, DLD-1, Colo206F, and HeLa lines (Vatalis, 2023).
    • Inhibition of endosomal acidification leads to reduced extracellular matrix pH maintenance and tumor cell invasiveness (Zhang et al., 2025).
    • Concanamycin A attenuates TRAIL-induced caspase activation, modulating apoptosis and cell death signaling in TRAIL-sensitive tumor cells (BCA-Protein, 2024).
    • Stock solutions are stable in DMSO or acetonitrile (1 mg/mL), but are not recommended for long-term storage; -20°C storage is advised (APExBIO).

    Applications, Limits & Misconceptions

    Concanamycin A is widely used in cancer biology research to dissect the roles of V-ATPase in cellular signaling, apoptosis, and therapeutic resistance. It is especially valuable in models where endosomal acidification and trafficking are critical determinants of phenotype. Applications include:

    • Studying V-ATPase-mediated signaling in cancer and immune cells.
    • Evaluating mechanisms of drug resistance related to endosomal/lysosomal function.
    • Probing links between proton pump activity, sphingolipid metabolism, and cell death pathways (see Vatalis, mechanism update).

    Common Pitfalls or Misconceptions

    • Concanamycin A is not a general apoptosis inducer: its effect is specific to V-ATPase-dependent pathways and may not induce cell death in cell types lacking active V-ATPase function.
    • It does not inhibit P-type or F-type ATPases; selectivity is limited to V-type H+-ATPases (APExBIO).
    • Long-term storage in solution can lead to compound degradation—use freshly prepared stocks when possible.
    • Solubility is limited; high concentrations may require warming to 37°C or ultrasonic bath treatment for full dissolution.
    • Not suitable for in vivo studies without further toxicological validation, as most data are cell-based.

    Workflow Integration & Parameters

    For optimal results, dissolve Concanamycin A in DMSO or acetonitrile at up to 1 mg/mL. For higher concentrations, warming to 37°C or brief ultrasonic bath treatments can enhance solubility. Stock solutions should be aliquoted and stored at -20°C, avoiding repeated freeze-thaw cycles. Experimental protocols typically employ 20 nM Concanamycin A for 60 minutes in cancer cell lines, but titration is recommended to confirm sensitivity in new models. APExBIO ships the A8633 kit on blue ice to maintain stability during transit. For detailed comparison of workflow optimization strategies and troubleshooting, this guide extends upon the standardized protocols discussed here by providing real-world reproducibility data.

    For advanced applications, Concanamycin A can be co-applied with chemotherapeutic agents or apoptosis inducers to elucidate V-ATPase-dependent resistance mechanisms. See this review for a broader overview of its use in sphingolipid regulatory research—a complement to the more focused mechanistic narrative here.

    Conclusion & Outlook

    Concanamycin A, as provided by APExBIO, is a benchmark tool for probing V-ATPase function and related pathways in cancer biology. Its high potency, selectivity, and well-documented protocol recommendations support reproducible, high-impact research on apoptosis induction, endosomal acidification, and intracellular trafficking. While its use is limited to in vitro and ex vivo systems due to solubility and toxicity considerations, ongoing studies aim to refine its application in combinatorial therapy and mechanistic dissection of V-ATPase-mediated signaling. For the latest updates on integration with sphingolipid regulatory science, see this recent article, which this dossier further extends with new mechanistic clarity.

    For ordering, detailed protocols, and additional technical documentation, consult the Concanamycin A product page.